My watch list  

Valeant Pharmaceuticals International

Valeant Pharmaceuticals International
Public company (NYSE:VRX)
Headquartersheadquarters Aliso Viejo, California, United States
Key peopleTimothy C. Tyson (CEO)
IndustryPharmaceutical industry
ProductsCesamet (nabilone) - Ribavirin (licensed to Schering Plough)
Revenue$US 683 million (2004)

Valeant Pharmaceuticals International is a pharmaceutical company with activities spanning the drug discovery pipeline from target identification through clinical trials and commercialization. The focus of the company is on neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of speciality chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s. The company has undergone major management, operational and strategic restructurings since the 1990s when shareholders of several group units approved the merger of ICN Pharmaceuticals, ICN Biomedicals, SPI Pharmaceuticals and Viratek into a new global entity, ICN Pharmaceuticals, the immediate forebear of Valeant. Kinerase(R), used kinetin as active is one of the most famous product of this company. for further in formation about kinerase, please visit

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Valeant_Pharmaceuticals_International". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE